Sixty-one MTC patients who experienced previous treatment with cabozantinib and/or vandetanib, 23 naïve MTC patients and 11 patients with RET fusion positive thyroid cancer were included in the efficacy analysis. This evidence concerns the gene RET and medullary thyroid gland carcinoma.